The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...

Corporate borrowers shrugged off fears over inflation and concerns over tariffs to print tight trades and pay for ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on UnitedHealth (UNH – Research Report) and Eli ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/31.CaE0WMJl.js ...